Cancer Immunotherapy

Question 1

Cancer Immunosurveillance

Answer 1

decreases cancer rates through inhibition of carcinogenesis and maintaing of cellular homeostasis

Question 2

Cancer can escape immunosurveillance by?

Answer 2

expression of immune checkpoint molecules (lowers MHC 1 expression0

Question 3

Cancer Immunotherapy is

Answer 3

biological therapy
helps restore immune system and does NOT target cancer cells directly

Question 4

Checkpoint Inhibitors?

Answer 4

takes brakes off immune system and attacks cancer cells
are all antibodies

Question 5

Chimeric antigen T-cell therapy

Answer 5

Cellular Immunotherapy

Question 6

Cytokines

Answer 6

IFNa and IL-2

Question 7

IFN a use?

Answer 7

completely resected high risk melanoma and refractory cancers

Question 8

IFN-a does what?

Answer 8

activates CD8 T cells and reduces Treg infiltration into tumor proliferation
AE: flu like

Question 9

IL2 use?

Answer 9

metastatic renal cell cancer and melanoma

Question 10

IL2 AE?

Answer 10

flu like symptoms
high doses=capillary leak syndrome or vascular leak —>low BP/swelling
Give=Glucocorticoids and IV fluids

Question 11

What are 2 important immune checkpoints?

Answer 11

CTLA-4 and PD-1

Question 12

When proteins interact with CTLA-4 and PD-1 the T-cells ______?

Answer 12

fall into sleep mode and dont attack the tumor

Question 13

Ipilimumab MOA?

Answer 13

blocks interaction of CTLA-4 with B7 ligands on APCs and augments T-cell activation

Question 14

Ipilimumab Use?

Answer 14

metastatic melanoma

Question 15

Ipilimumab AE?

Answer 15

inflammatory toxicities-immune related

Question 16

Nivolumab MOA?

Answer 16

blocks the interaction between PD-1 and PD-L1

Question 17

Nivolumab is more effective and safer than Ipilimumab

Answer 17

True

Question 18

Are immune AE less common with Nivolumab?

Answer 18

Yes

Question 19

Nivolumab Use?

Answer 19

For previously treated advanced NSCLC and RCC

Question 20

Cancers with mismatch repair deficiency or high microsatellite instability give?

Answer 20

Pembrolizumab

Question 21

Give Pembrolizumab for?

Answer 21

Unresectable or metastatic melanoma previously treated with Ipilmumab

Question 22

Pembrolizumab AE?

Answer 22

Fetal risk

Question 23

Atezolimumab AE?

Answer 23

potential embryo fetal toxicity

Question 24

PD-L1 is expressed in _______?

Answer 24

Cancer cells

Question 25

Combo treatment with Anti-PD1 and Anti-CTLA4 does what?

Answer 25

improves efficacy